


Prinomastat

Chemical Properties

CAS No. :	192329-42-3
Formula:	C ₁₈ H ₂₁ N ₃ O ₅ S ₂
Molecular Weight:	423.51
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Prinomastat (AG3340) is an orally active and selective inhibitor of metalloproteinases (MMPs) that crosses the blood-brain barrier.
Targets(IC50)	Apoptosis,MMP
In vitro	In C57MG/Wnt1 cells, Prinomastat (0.1 µg/mL, 1 µg/mL; 4 days) significantly decreases MMP-3 promoter activity[1].
In vivo	In a human fibrosarcoma mouse model (HT1080), Prinomastat (50 mg/kg; intraperitoneal injection) is well tolerated by the animals, and exhibits significant tumor growth inhibition. It has a short half-life of 1.6 hours.

Solubility Information

Solubility	DMSO: 1 mg/mL (2.36 mM),Sonication is recommended. H ₂ O: 1 mg/mL (2.36 mM),when pH is adjusted to 3 with HCl. Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3612 mL	11.8061 mL	23.6122 mL
5 mM	0.4722 mL	2.3612 mL	4.7224 mL
10 mM	0.2361 mL	1.1806 mL	2.3612 mL
50 mM	0.0472 mL	0.2361 mL	0.4722 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. *Bioorg Med Chem*. 2003 Dec 1;11(24):5461-84.

Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). *Cancer Biol Ther*. 2010 Jul 15;10(2):198-208.

Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. *Ann N Y Acad Sci*. 1999 Jun 30;878:236-70.

Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. *Curr Eye Res*. 2000 Jun;20(6):447-53.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481